Brokerages expect Novocure Ltd (NASDAQ:NVCR) to announce ($0.16) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Novocure’s earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.15). Novocure reported earnings per share of ($0.12) in the same quarter last year, which would suggest a negative year-over-year growth rate of 33.3%. The company is expected to issue its next earnings report on Thursday, February 28th.

On average, analysts expect that Novocure will report full-year earnings of ($0.68) per share for the current year, with EPS estimates ranging from ($0.69) to ($0.67). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.07) per share, with EPS estimates ranging from ($0.26) to $0.15. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Novocure.

Novocure (NASDAQ:NVCR) last posted its quarterly earnings data on Thursday, October 25th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. Novocure had a negative return on equity of 52.72% and a negative net margin of 25.37%. The firm had revenue of $64.76 million for the quarter, compared to analysts’ expectations of $65.61 million.

NVCR has been the topic of a number of analyst reports. Wedbush lifted their price objective on Novocure from $55.00 to $58.00 and gave the company an “outperform” rating in a research report on Friday, October 26th. Wells Fargo & Co lifted their price objective on Novocure from $40.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday, September 6th. BidaskClub raised Novocure from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 16th. Mizuho reaffirmed a “buy” rating and set a $58.00 price objective on shares of Novocure in a research report on Thursday, September 6th. Finally, ValuEngine cut Novocure from a “strong-buy” rating to a “buy” rating in a research report on Friday, October 19th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $48.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC lifted its holdings in Novocure by 37.9% in the 3rd quarter. FMR LLC now owns 10,845,246 shares of the medical equipment provider’s stock worth $568,292,000 after purchasing an additional 2,983,125 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Novocure by 9.6% in the 3rd quarter. Vanguard Group Inc. now owns 5,424,908 shares of the medical equipment provider’s stock worth $284,265,000 after purchasing an additional 476,635 shares in the last quarter. BlackRock Inc. lifted its holdings in Novocure by 2.8% in the 3rd quarter. BlackRock Inc. now owns 4,749,934 shares of the medical equipment provider’s stock worth $248,897,000 after purchasing an additional 129,388 shares in the last quarter. Baillie Gifford & Co. lifted its holdings in Novocure by 14.0% in the 3rd quarter. Baillie Gifford & Co. now owns 3,527,100 shares of the medical equipment provider’s stock worth $184,821,000 after purchasing an additional 433,705 shares in the last quarter. Finally, Capital World Investors lifted its holdings in Novocure by 20.6% in the 3rd quarter. Capital World Investors now owns 2,265,311 shares of the medical equipment provider’s stock worth $118,702,000 after purchasing an additional 386,600 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

Shares of NVCR stock traded down $0.77 during trading hours on Friday, reaching $33.63. 663,841 shares of the company traded hands, compared to its average volume of 621,167. Novocure has a 12-month low of $19.06 and a 12-month high of $53.70. The company has a quick ratio of 5.72, a current ratio of 6.17 and a debt-to-equity ratio of 1.30. The stock has a market cap of $3.20 billion, a P/E ratio of -48.04 and a beta of 3.73.

Novocure Company Profile

Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St.

See Also: Ex-Dividend

Get a free copy of the Zacks research report on Novocure (NVCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.